Q4 2022 Results
Company overview
Financial review
2023 priorities
Appendix
Sandoz 2023 and mid-term guidance
Expected, barring unforeseen events; growth vs. PY in cc
2023
Mid-term
Sales expected to grow low-to-mid single digit
Core Oplnc expected to decline low double digit, reflecting required
stand-up investments to transition Sandoz to a separate company and
continued inflationary pressures
Sales expected to grow low-to-mid single digit CAGR
Core Oplnc margin expected to expand to mid 20s, continuously progressing from
the low 2023 base driven by continued Sales growth and operational efficiencies
Key assumptions:
We continue to expect that the planned Sandoz spin-off is completed in H2 2023
Note: after completion of planned Sandoz spin-off, Core Oplnc guidance will be expressed in terms of core EBITDA.
42 Investor Relations | Q4 2022 Results
FINANCIAL PROFILE
1 NOVARTIS | Reimagining MedicineView entire presentation